Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

— First Large Phase 2 Study of an Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Improvements in Wakefulness and Excessive Daytime Sleepiness Compared to Placebo in Narcolepsy Type 2 — — Improvements in Wakefulness and Patient-Reported Cognition and Fatigue Were Sustained Through 13 Weeks — — Alixorexton Was Generally Well Tolerated at All Doses Tested —